Sanjana Pannem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sanjana Pannem has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Kimberley S. Samkoe
Thayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA
2 shared publications - Yichen Feng
Dartmouth College, Geisel School of Medicine, Hanover, New Hampshire, United States
2 shared publications - Adrianna L. De La Torre
Department of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA
1 shared publication - Catherine C. Y. Chang
Department of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA
1 shared publication - Cody C. Rounds
Department of Biomedical Engineering, Oregon Health and Science University (OHSU), Portland OR 97239, USA
1 shared publication - Darcy B. Pooler
Clinical Pharmacology Shared Resource, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03766, USA
1 shared publication
Latest Publications
- Open Access
- 29 March 2025
- Published by SPIE-Intl Soc Optical Eng in Journal of Biomedical Optics
- Vol. 30 (04) , 046001-16
Dual-channel pulse-dye densitometry can enable correction of fluorescent targeted and control agent plasma input function differences for quantitative paired-agent molecular imaging: a simulation study
In recent years, paired-agent imaging (PAI) strategies have been explored owing to their ability to yield quantitative in vivo imaging of cell-surface receptors.1 – 3 PAI requires the administration of at least two imaging agents of similar blood and tissue kinetics where one agent is targeted to a biomolecule of interest and one is untargeted (the “control” agent). By measuring the dynamics of the control agent, non-specific accumulation of the targeted agent and variable targeted agent delivery (attributable to the variability of blood flow and vascular permeability among tissues, particularly cancerous tissues) can potentially be accounted for, allowing for more quantitative estimates of the targeted agent’s specific binding through the approximation of a quantity termed the “binding potential” (BP). BP is directly proportional to the concentration of an agent’s biomolecular target,4 and as such, the measurement of this quantity can give critical insight into the disease state and phenotype of a biological tissue. In the context of surgical oncology, BP mapping (compared with targeted agent distribution mapping) may enable improved discrimination between malignant and non-malignant tissue types.5,6
- 29 March 2025
- Published by SPIE-Intl Soc Optical Eng in Journal of Biomedical Optics
- Vol. 30 (04) , 046001-16
Open AccessDual-channel pulse-dye densitometry can enable correction of fluorescent targeted and control agent plasma input function differences for quantitative paired-agent molecular imaging: a simulation study
In recent years, paired-agent imaging (PAI) strategies have been explored owing to their ability to yield quantitative in vivo imaging of cell-surface receptors.1 – 3 PAI requires the administration of at least two imaging agents of similar blood and tissue kinetics where one agent is targeted to a biomolecule of interest and one is untargeted (the “control” agent). By measuring the dynamics of the control agent, non-specific accumulation of the targeted agent and variable targeted agent delivery (attributable to the variability of blood flow and vascular permeability among tissues, particularly cancerous tissues) can potentially be accounted for, allowing for more quantitative estimates of the targeted agent’s specific binding through the approximation of a quantity termed the “binding potential” (BP). BP is directly proportional to the concentration of an agent’s biomolecular target,4 and as such, the measurement of this quantity can give critical insight into the disease state and phenotype of a biological tissue. In the context of surgical oncology, BP mapping (compared with targeted agent distribution mapping) may enable improved discrimination between malignant and non-malignant tissue types.5,6
- 1 January 2025
- Published by Optica Publishing Group
- p. OTh1D.3
Advancing Paired Agent Imaging for Head and Neck Cancer
Paired Agent Imaging was tested in in vivo mouse models, demonstrating consistent binding potential (BP) quantification across increasing dosage, stable BP quantification at timepoints >5h, and no significant effects due to injection methodology.
- 1 January 2025
- Published by Optica Publishing Group
- p. OTh1D.3
Advancing Paired Agent Imaging for Head and Neck Cancer
Paired Agent Imaging was tested in in vivo mouse models, demonstrating consistent binding potential (BP) quantification across increasing dosage, stable BP quantification at timepoints >5h, and no significant effects due to injection methodology.
- Open Access
- 2 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 11013
Stealth Liposomes Encapsulating a Potent ACAT1/SOAT1 Inhibitor F12511: Pharmacokinetic, Biodistribution, and Toxicity Studies in Wild-Type Mice and Efficacy Studies in Triple Transgenic Alzheimer’s Disease Mice
Cholesterol is essential for cellular function and is stored as cholesteryl esters (CEs). CEs biosynthesis is catalyzed by the enzymes acyl-CoA:cholesterol acyltransferase 1 and 2 (ACAT1 and ACAT2), with ACAT1 being the primary isoenzyme in most cells in humans. In Alzheimer’s Disease, CEs accumulate in vulnerable brain regions. Therefore, ACATs may be promising targets for treating AD. F12511 is a high-affinity ACAT1 inhibitor that has passed phase 1 safety tests for antiatherosclerosis. Previously, we developed a nanoparticle system to encapsulate a large concentration of F12511 into a stealth liposome (DSPE-PEG2000 with phosphatidylcholine). Here, we injected the nanoparticle encapsulated F12511 (nanoparticle F) intravenously (IV) in wild-type mice and performed an HPLC/MS/MS analysis and ACAT enzyme activity measurement. The results demonstrated that F12511 was present within the mouse brain after a single IV but did not overaccumulate in the brain or other tissues after repeated IVs. A histological examination showed that F12511 did not cause overt neurological or systemic toxicity. We then showed that a 2-week IV delivery of nanoparticle F to aging 3xTg AD mice ameliorated amyloidopathy, reduced hyperphosphorylated tau and nonphosphorylated tau, and reduced neuroinflammation. This work lays the foundation for nanoparticle F to be used as a possible therapy for AD and other neurodegenerative diseases.
- 2 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 11013
Open AccessStealth Liposomes Encapsulating a Potent ACAT1/SOAT1 Inhibitor F12511: Pharmacokinetic, Biodistribution, and Toxicity Studies in Wild-Type Mice and Efficacy Studies in Triple Transgenic Alzheimer’s Disease Mice
Cholesterol is essential for cellular function and is stored as cholesteryl esters (CEs). CEs biosynthesis is catalyzed by the enzymes acyl-CoA:cholesterol acyltransferase 1 and 2 (ACAT1 and ACAT2), with ACAT1 being the primary isoenzyme in most cells in humans. In Alzheimer’s Disease, CEs accumulate in vulnerable brain regions. Therefore, ACATs may be promising targets for treating AD. F12511 is a high-affinity ACAT1 inhibitor that has passed phase 1 safety tests for antiatherosclerosis. Previously, we developed a nanoparticle system to encapsulate a large concentration of F12511 into a stealth liposome (DSPE-PEG2000 with phosphatidylcholine). Here, we injected the nanoparticle encapsulated F12511 (nanoparticle F) intravenously (IV) in wild-type mice and performed an HPLC/MS/MS analysis and ACAT enzyme activity measurement. The results demonstrated that F12511 was present within the mouse brain after a single IV but did not overaccumulate in the brain or other tissues after repeated IVs. A histological examination showed that F12511 did not cause overt neurological or systemic toxicity. We then showed that a 2-week IV delivery of nanoparticle F to aging 3xTg AD mice ameliorated amyloidopathy, reduced hyperphosphorylated tau and nonphosphorylated tau, and reduced neuroinflammation. This work lays the foundation for nanoparticle F to be used as a possible therapy for AD and other neurodegenerative diseases.